ARS Pharmaceuticals IPO

ARS pharmaceuticals is developing an intranasal epinephrine spray for patients at-risk of severe allergic reactions to food, medications and insect bites that could lead to anaphylaxis.

Register for Details

For more details on financing and valuation for ARS Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about ARS Pharmaceuticals

Forge green plus iconForge green minus icon

What is ARS Pharmaceuticals's IPO price?

ARS Pharmaceuticals's IPO price is $6.08 as of 1/18/24.
Forge green plus iconForge green minus icon

What is ARS Pharmaceuticals's funding to date?

ARS Pharmaceuticals has raised $76.55MM to date.
Forge green plus iconForge green minus icon

When was ARS Pharmaceuticals founded?

ARS Pharmaceuticals was founded in 2015.

ARS Pharmaceuticals Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
8/31/2021 Series D $55MM raised $XXX.XX $XXX.XX
9/14/2018 Series C $20.15MM raised $XXX.XX $XXX.XX
4/30/2018 Series B $1,000K raised $XXX.XX $XXX.XX
4/30/2016 Series A $396.84K raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Nov 15, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.